Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs)

Lung Cancer

Volumn 104, Issue , 2017, Pages 24-30

  Tiseo, Marcello ^a   Damato, Angela ^a   Longo, Lucia ^b   Barbieri, Fausto ^c   Bertolini, Federica ^c   Stefani, Alessandro ^c   Migaldi, Mario ^c   Gnetti, Letizia ^a   Camisa, Roberta ^a   Bordi, Paola ^a   Buti, Sebastiano ^a   Rossi, Giulio ^d  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b AUSL Modena   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d Aosta Hospital   (Italy)

Author keywords

c KIT; Gene mutations; PD L1; Thymic carcinoma; Thymoma

Indexed keywords

ALK PROTEIN; B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; K RAS PROTEIN; OCTREOTIDE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN; SCATTER FACTOR RECEPTOR; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG; ANAPLASTIC LYMPHOMA KINASE; PROTEIN TYROSINE KINASE; STEM CELL FACTOR RECEPTOR;

ADJUVANT RADIOTHERAPY; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL FEATURE; EPITHELIUM TUMOR; EXON; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SURVIVAL; THYMIC EPITHELIAL TUMOR; THYMOMA; CANCER STAGING; METABOLISM; MIDDLE AGED; MUTATION; NEOPLASM; PATHOLOGY; SURVIVAL ANALYSIS; THYMUS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD274; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR PROTEIN-TYROSINE KINASES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; THYMOMA; THYMUS GLAND; THYMUS NEOPLASMS;

EID: 85007564293     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2016.12.005     Document Type: Article

References (35)

1. [1] Engels, E.A., Epidemiology of thymoma and associated malignancies. J. Thorac. Oncol. 5 (2010), S260–265.
2. [2] Travis, W.D., Brambilla, E., Muller-Hermelink, H.K., Harris, C.C., Pathology and genetics: tumors of the lung, pleura, thymus and heart. Kleihues, P., Sobin, L.H., (eds.) World Health Organization Classification of Tumours, 2004, IARC Press, Lyon, 145–247.
3. [3] Suster, S., Moran, C.A., Thymoma, atypical thymoma, and thymic carcinoma: a novel conceptual approach to the classification of thymic epithelial neoplasms. Am. J. Clin. Pathol. 111 (1999), 826–833.
4. [4] Kelly, R.J., Petrini, I., Rajan, A., Wang, Y., Giaccone, G., Thymic malignancies: from clinical management to targeted therapies. J. Clin. Oncol. 29 (2011), 4820–4827.
5. [5] Postow, M.A., Callahan, M.K., Wolchok, J.D., Immune checkpoint blockade in cancer therapy. J. Clin. Oncol. 33 (2015), 1974–1982.
6. [6] Katsuya, Y., Fujita, Y., Horinouchi, H., Ohe, Y., Watanabe, S., Tsuta, K., Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma. Lung Cancer 88 (2015), 154–159.
7. [7] Wynes, M.W., Sholl, L.M., Dietel, M., et al. An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators. J. Thorac. Oncol. 9 (2014), 631–638.
8. [8] Buti, S., Donini, M., Sergio, P., et al. Impressive response with Imatinib in a heavily pretreated patient with metastatic c-KIT mutated thymic carcinoma. J. Clin. Oncol. 29 (2011), e803–e805.
9. [9] Rossi, G., Donini, M., Sergio, P., et al. When a thymic carcinoma becomes a GIST. Lung Cancer 10 (2013), 6–10 (8).
10. [10] Bisagni, G., Rossi, G., Cavazza, A., et al. Long lasting response to the multikinase inhibitor bay 43–9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma. J. Thorac. Oncol. 4 (2009), 773–775.
11. [11] Girard, N., Shen, R., Guo, T., et al. Comprehensive genomic analysis reveal clinically relevant molecular distinctions between thymic and thymomas. Clin. Cancer Res. 15 (2009), 6790–6799.
12. [12] Gilhus, N.E., Jones, M., Turley, H., et al. Oncogene proteins and proliferation antigens in thymomas: increase expression of epidermal growth factor receptor and Ki67 antigen. J. Clin. Pathol. 48 (1995), 447–455.
13. [13] Henley, J.D., Koukoulis, G.K., Loehrer, P.J. Sr., Epidermal growth factor receptor expression in invasive thymoma. J. Cancer Res. Clin. Oncol. 128 (2002), 167–170.
14. [14] Aisner, S.C., Dahlberg, S., Hameed, M.R., et al. Epidermal growth factor receptor, c-KIT and HER2/neu immunostaining in advanced or recurrent thymic epithelial neoplasm staged according to the 2004 World Health Organization in patients treated with octreotide and prednisone: an Eastern Cooperative Oncology Group study. J. Thorac. Oncol. 5 (2010), 885–892.
15. [15] Suzuki, E., Sasaki, H., Kawano, O., et al. Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors. Jpn. J. Clin. Oncol. 36 (2006), 351–356.
16. [16] Meister, M., Schirmacher, P., Dienemann, H., et al. Mutational status of the epidermal growth factor receptor (EGFR) gene in thymomas and thymic carcinomas. Cancer Lett. 248 (2007), 186–191.
17. [17] Yoh, K., Nishiwaki, Y., Ishii, G., et al. Mutational status of EGFR and KIT in thymoma and thymic carcinoma. Lung Cancer 62 (2008), 316–320.
18. [18] Yamaguchi, H., Soda, H., Kitazaki, T., et al. Thymic carcinoma with epidermal growth factor receptor gene mutation. Lung Cancer 52 (2006), 261–262.
19. [19] Lopez-Chavez, A., Thomas, A., Rajan, A., et al. Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multi-arm, multi-histology phase II basket trial. J. Clin. Oncol. 33 (2015), 1000–1007.
20. [20] Pan, C.C., Chen, P.C., Wang, L.S., Lee, J.Y., Chiang, H., Expression of apoptosis-related markers and HER-2/neu in thymic epithelial tumors. Histopathology 43 (2003), 165–172.
21. [21] Weissferdt, A., Lin, H., Woods, D., et al. HER family receptor, and ligand status in thymic carcinoma. Lung Cancer 77 (2012), 515–521.
22. [22] Mimae, T., Tsuta, K., Kondo, T., et al. Protein expression and gene copy number changes of receptor tyrosine kinase in thymomas and thymic carcinomas. Ann. Oncol. 23 (2012), 3129–3137.
23. [23] Asao, T., Fujiwara, Y., Sunami, K., et al. Medical treatment involving investigational drug and genetic profile of thymic carcinoma. Lung Cancer 93 (2012), 77–81.
24. [24] Sasaki, H., Yano, M., Fujii, Y., Evaluation of Kras gene mutation and copy number in thymic carcinomas and thymomas. J. Thorac. Oncol. 5 (2010), 1715–1716.
25. [25] Meister, M., Kahl, P., Muley, T., et al. Expression and mutational status of PDGFR in thymic tumours. Anticancer Res. 29 (2009), 4057–4061.
26. [26] Schirosi, L., Nannini, N., Nicoli, D., et al. Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors. Ann. Oncol. 23 (2012), 2409–2414.
27. [27] Strobel, P., Bargou, R., Wolff, A., et al. Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience. Br. J. Cancer 103 (2010), 196–200.
28. [28] Facchinetti, F., Marabelle, A., Rossi, G., et al. Moving immune checkpoint blockade in thoracic tumors beyond NSCLC. J. Thorac. Oncol.(June), 2016 Epub ahead of print.
29. [29] Weksler, B., Lu, B., Alterations of the immune system in thymic malignancies. J. Thorac. Oncol. 9:9 Suppl. 2 (2014), S137–42.
30. [30] Brown, J.A., Dorfman, D.M., Ma, F.R., et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J. Immunol. (Baltimore, MD 1950) 170:3 (2003), 1257–1266.
31. [31] Padda, S.K., Riess, J.W., Schwartz, E.J., et al. Diffuse high intensity PD-L1 staining in thymic epithelial tumors. J. Thorac. Oncol. 10:3 (2015), 500–508.
32. [32] Yokoyama, S., Miyoshi, H., Nishi, T., et al. Clinico-pathologic and prognostic implication of programmed death ligand 1 expression in thymoma. Ann. Thorac. Surg. 101:4 (2016), 1361–1369.
33. [33] Yokoyama, S., Miyoshi, H., Nakashima, K., et al. Prognostic value of programmed death ligand 1 and programmed death 1 expression in thymic carcinoma. Clin. Cancer Res., 2016 (Published Online First).
34. [34] Velcheti, V., Rimm, D.L., Schalper, K.A., Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1). J. Thorac. Oncol. 8 (2013), 803–805.
35. [35] Mansfield, A.S., Roden, A.C., Peikert, T., et al. B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. J. Thorac. Oncol. 9 (2014), 1036–1040.